Eyenovia reports first quarter 2024 financial results and provides updates on its myopia phase iii program and its two fda approved commercial products, mydcombi and clobetasol

Remains on track towards accelerating development of its late-stage product candidate in the multi-billion-dollar pediatric progressive myopia market, micropine

EYEN Ratings Summary

EYEN Quant Ranking